Glaxosmithkline | GSK - Cost Of Sales



Glaxosmithkline reported GBP2.16B in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
AbbVie USD 4.35B 344M Jun/2025
Amgen USD 3.01B 406M Jun/2025
AstraZeneca USD 2.47B 232M Jun/2025
Aurora Cannabis CAD 70.07M 8.78M Jun/2025
Bausch Health Companies USD 764M 63M Jun/2025
Bristol-Myers Squibb USD 3.37B 339M Jun/2025
Canopy Growth CAD 54.1M 3.44M Jun/2025
Corcept Therapeutics USD 3.43M 1.03M Jun/2025
Drreddys Laboratories INR 36.83B 2.29B Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
GlaxoSmithKline GBP 2.16B 241M Jun/2025
Glaxosmithkline GBP 2.16B 363M Jun/2025
J&J USD 7.6B 304M Jun/2025
Merck USD 2.82B 53M Jun/2025
Novartis USD 3.32B 95M Jun/2025
Pacira USD 55.19M 20.88M Jun/2025
Perrigo USD 693.4M 41.8M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
Prestige Brands USD 114.38M 12.13M Jun/2025
Roche Holding CHF 4.13B 393.5M Dec/2024
Sanofi EUR 2.99B 103M Jun/2025
Supernus Pharmaceuticals USD 37.65M 21.88M Jun/2025
Takeda JPY 384.68B 2.6B Jun/2025
Teva Pharmaceutical Industries USD 2.07B 97M Jun/2025
Zoetis USD 682M 60M Jun/2025